Search results
Found 25 matches for
While research has already established that B vitamin supplements can help slow mental decline in older people with memory problems, an international team have now found that having higher levels of Omega-3 fatty acids in your body could boost the B vitamins' effect.
Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections
14 November 2022
New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.
Brain regions related to smell show decline following mild COVID-19
7 March 2022
Researchers from the University of Oxford have used data from UK Biobank participants to look at changes to the brain on average 4.5 months after mild SARS-CoV-2 infection.
Attention and memory deficits persist for months after recovery from mild COVID
19 January 2022
Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.
Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia
17 December 2021
A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.
Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize
19 November 2021
In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.
COVID-19 infection has greater risk than vaccines of causing very rare neurological events
27 October 2021
Research reveals risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.
International study finds insomnia, anxiety and depression very prevalent during first phase of COVID-19 pandemic
10 September 2021
Researchers are recommending public health interventions to reduce the long-term adverse outcomes associated with chronic insomnia and mental health problems.
Developing diagnostics for COVID-19
26 November 2020
Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.
COVID-19 and Guillain-Barré syndrome
23 November 2020
Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.
Low-cost ventilator wins at E&T Innovation Awards
20 November 2020
The OxVent is a rapidly deployable and scalable low-cost mechanical ventilator specially designed for COVID-19, which has now been recognised as one of the best innovations of the year by the Institute of Engineering and Technology.
Viruses shown to evolve as a result of different immune responses in different ethnic populations
20 November 2020
New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.
Six-month outcomes after treatment for COVID-19 on intensive care units in England
21 July 2020
Researchers at the University of Oxford are investigating the long-term health outcomes for patients who have been treated for severe COVID-19 disease in intensive care. Finding out whether these outcomes differ from those of other patients who have survived critical care will help to inform clinical practice and appropriate follow-up care.
New COVID-19 simulation training for smartphones helps African healthcare workers save lives
6 July 2020
The University of Oxford's LIFE project has launched a new set of app-based training scenarios that help healthcare workers in Africa safely manage and treat cases of children with suspected COVID-19
Motorsport technology helps keep COVID-19 clinicians safe
18 June 2020
Staff at our Oxford Simulation,Teaching & Research centre (OxSTaR) helped to develop this new type of aerosol shield designed by Formula One motor racing engineers
Effects of COVID-19 on sleep: Oxford researchers lead international study
11 June 2020
An international group of researchers led by Professor Colin Espie is investigating the impact of the COVID-19 pandemic on sleep and daily rhythms in adults.
Oxford leads part of major COVID-19 drugs trial
10 June 2020
As part of the UK NIHR multi-arm, multi-stage CATALYST Trial, researchers at the University of Oxford will investigate whether administering the anti-inflammatory drug infliximab to patients with COVID-19 can prevent progression to respiratory failure or death.
COVID-19 drug trial could lead to enhanced respiratory care for patients
29 May 2020
Researchers including Stuart McKechnie and Matthew Rowland from our Critical Care Research Group are carrying out a new drug trial aimed at treating COVID-19, funded by LifeArc.
Using MRI to investigate the effect of COVID-19 on the brain
1 May 2020
A team of our neuroimaging researchers will lead this study, which has received a grant from the University of Oxford's COVID-19 Research Response Fund.
Studying the impact of COVID-19 on epilepsy
30 April 2020
NDCN researchers lead a global study based on analysing survey data